ART DECO

Randomised multicentre accelerated radiotherapy study of dose escalated intensity modulated radiotherapy versus standard dose intensity modulated radiotherapy in patients receiving treatment for locally advanced laryngeal and hypopharyngeal cancers.

Disease site: Head and neck cancer

Treatment Modality:

Status: In follow-up

Trial Details

ART DECO is a phase III, multicentre, randomised controlled trial to determine the potential of dose escalated intensity-modulated radiotherapy (IMRT) to improve locoregional failure free rate and laryngeal preservation in patients with locally advanced laryngeal and hypopharyngeal cancers, without increasing the incidence of severe acute and late toxicities to unacceptable levels.

ART DECO recruited 276 patients and closed to recruitment in October 2015. Participants are now being followed up for at least a further 5 years. In ART DECO, patients received either dose escalated IMRT or standard dose IMRT. Dose escalated IMRT delivered 67.2 Gy in 28 fractions to the involved site and nodal groups, and 56 Gy in 28 fractions to nodal areas at risk of harbouring microscopic disease; standard dose IMRT was lower.

Further Information

Chief Investigator: Professor Christopher Nutting, The Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Dr Emma Hall

Trial Management Contact: [email protected]

ISRCTN: 01483375

Sponsor: The Royal Marsden NHS Foundation Trust

Funding: Cancer Research UK (CRUK/10/018)

View ART DECO on the National Institute for Health Research website: NIHR - Be Part Of Research

A plain English summary is available from Cancer Research UK.

Publications and Presentations

Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.  Christopher M. Nutting, Clare L. Griffin, Paul Sanghera, Bernadette Foran, Matthew Beasley, David Bernstein, Vivian Cosgrove, Shelia Fisher, Catherine M. West, Amen Sibtain, Nachi Palaniappan, Teresa Guerrero Urbano, Mehmet Sen, Win Soe, Mohammed Rizwanullah, Katie Wood, Shanmugasundaram Ramkumar, Elizabeth Junor, Audrey Cook, Tom Roques, Christopher Scrase, Shreerang A. Bhide, Dorothy Gujral, Kevin J. Harrington, Hisham Mehanna, Aisha Miah, Marie Emson, Deborah Gardiner, James P. Morden, Emma Hall on behalf of the ART DECO Trial Management Group. European Journal of Cancer, Volume 153, August 2021, Pages 242-256.
Red, yellow and blue microscope image of immunofluorescence staining showing extension of prostatic adenocarcinoma into the bladder wall
New drug hope for prostate cancer patients

10/01/25

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical Cancer Research.
See full story
Left: Plates showing the impact of olaparib on BRCA cancer cells and minimal impact of on healthy cells. (Right) Lynparza, olaparib's brand name, drug packaging. Photo credit: Science Museum Group
ICR welcomes NICE recommendation of olaparib for advanced breast cancer

09/01/25

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.
See full story